Market research
HBQ.F Hofseth BioCare ASA
F EUR Consumer Defensive
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 52M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.25
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- ISIN
- NO0010598683
- Market cap
- 52M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.25
About
About Hofseth BioCare ASA
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, Turkey, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a fish oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are calcium collagen complexes that support joint and bone health; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was founded in 2000 and is headquartered in Ålesund, Norway.
Research context
Hofseth BioCare ASA appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the HBQ.F discussion.
5 years, 7 months ago
Hofseth BioCare ASA is currently in a long term downtrend where the price is trading 5.2% below its 200 day moving average.
From a valuation standpoint, the stock is 96.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 41.6.
Hofseth BioCare ASA's total revenue rose by 106.9% to $23M since the same quarter in the previous year.
Its net income has increased by 7.1% to $-31M since the same quarter in the previous year.
Finally, its free cash flow fell by 3.2% to $-24M since the same quarter in the previous year.
Based on the above factors, Hofseth BioCare ASA gets an overall score of 3/5.